The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease

• Sponsor: Turkish Ophthalmology Society (Other)
• Overall Status: Completed
• CT.gov ID: NCT01720628
• Collaborator: (none)
• Enrollment: 86
• Location: 1
• Duration (Months): 3
• Patients Per Site Per Month: 28.5

Study Details

Study Description

Brief Summary

Objectives: Behçet's disease (BD) is a systemic vasculitis. Since vascular endothelial dysfunction plays a prominent role in the pathogenesis of the disease, we considered angiogenic cytokines as an interesting target for investigation in BD. The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.

Design and Methods: Sixty five patients with BD and 21 healthy control subjects were included in the study. Serum angiogenin, bFGF and VEGF concentrations were determined by using in vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.

Condition or Disease	Intervention/Treatment	Phase
Behçet's Disease	Other: serum levels of angiogenin, bFGF, VEGF

Study Design

• Study Type: Observational
• Actual Enrollment: 86 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Study Start Date: Nov 1, 2011
• Actual Primary Completion Date: Nov 1, 2011
• Actual Study Completion Date: Feb 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Behçet's patients Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group	Other: serum levels of angiogenin, bFGF, VEGF; Behçet's patients

Outcome Measures

Primary Outcome Measures

1. Serum levels of angiogenin in Behçet's patients with or without ocular involvement [1 year]

   The median serum angiogenin level was significantly higher in all patients with BD than controls (P=0.001). However there was no statistically significant difference between all patients and patients with or without ocular involvement. The mean serum bFGF and the median serum VEGF levels were higher in patients with ocular involvement than all patients, patients without ocular involvement and controls. But these differences did not reach statistical significance.

Secondary Outcome Measures

1. Serum levels of bFGF in Behçet's patients with or without ocular involvement [1 year]

Other Outcome Measures

1. Serum levels of VEGF in Behçet's patients with or without ocular involvement [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• age between 18-65

• fulfilling the international diagnostic criteria for Behçet's disease

Exclusion Criteria:

• to have another systemic disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ankara University, Faculty of Medicine, Department of Ophthalmology	Ankara		Turkey	06620

Sponsors and Collaborators

• Turkish Ophthalmology Society

Investigators

• Study Director: ali yalçındağ, * Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Clinical Biochemistry

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Yeşim Gedik Oğuz, MD, Turkish Ophthalmology Society
• ClinicalTrials.gov Identifier: NCT01720628
• Other Study ID Numbers: AFV-5813
• First Posted: Nov 2, 2012
• Last Update Posted: Nov 2, 2012
• Last Verified: Oct 1, 2012

• Keywords provided by Yeşim Gedik Oğuz, MD, Turkish Ophthalmology Society: Angiogenin, Behçet's disease, bFGF, VEGF
• Additional relevant MeSH terms: Behcet Syndrome; Angiogenin

Study Results

No Results Posted as of Nov 2, 2012